Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 8/20 | 0.49 |
| ▸ | MAP4K2 | Q12851 | 8/20 | 0.49 |
| ▸ | CLK2 | P49760 | 7/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 7/20 | 0.49 |
| ▸ | LCK | P06239 | 7/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 6/20 | 0.49 |
| ▸ | MET | P08581 | 6/20 | 0.49 |
| ▸ | RET | P07949 | 5/20 | 0.49 |
| ▸ | GSK3B | P49841 | 5/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.49 |
| ▸ | CSF1R | P07333 | 5/20 | 0.49 |
| ▸ | GSK3A | P49840 | 4/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.49 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.49 |
| ▸ | ABL1 | P00519 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27010990 | 0.80 | ELANE (0.40) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL6643678 | 0.79 | ELANE (0.39) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL14968875 | 0.79 | MAPT (0.49) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL1901292 | 0.76 | MAP4K4 (0.53) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL869609 | 0.73 | KDR (0.54) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL15743285 | 0.73 | MAP4K4 (0.50) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL11202279 | 0.72 | ESR1 (0.49) | ELANE | |
| SCHEMBL3868631 | 0.72 | MAP4K4 (0.57) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL14293291 | 0.72 | MAP4K4 (0.53) | KDRMAP4K4MAP4K2CLK2CLK4 | |
| SCHEMBL15743366 | 0.72 | KDR (0.53) | KDRMAP4K4MAP4K2CLK2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112351-B1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-03-30 | — | — | EP | disclosed |
| US-9914707-B2 | Naphthylamide compound, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-03-13 | — | — | US | disclosed |
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | KDR 3297/4885MAP4K4 265/4885MAP4K2 244/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | KDR 3297/4885MAP4K4 265/4885MAP4K2 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.